BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Chandra P, Enespa, Singh R, Arora PK. Microbial lipases and their industrial applications: a comprehensive review. Microb Cell Fact 2020;19:169. [PMID: 32847584 DOI: 10.1186/s12934-020-01428-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 23.0] [Reference Citation Analysis]
2 Pandey M, Konrad S, Reed N, Ahenakew V, Isbister P, Isbister T, Gallagher L, Campbell T, Skinner S. Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care. Health Promot Int 2021:daab074. [PMID: 34125199 DOI: 10.1093/heapro/daab074] [Reference Citation Analysis]
3 Petrosyan Y, Simmons J, Kelly E, Cooper CL. Uptake and factors associated with direct-acting antiviral therapy for hepatitis C and treatment outcomes among Canadian immigrants: A retrospective cohort analysis. CanLivJ. [DOI: 10.3138/canlivj-2021-0037] [Reference Citation Analysis]
4 Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health 2021;20:81. [PMID: 33740984 DOI: 10.1186/s12939-021-01420-7] [Reference Citation Analysis]
5 Apau Bediako R. The Ethics of Screening and Treating Persons with Hepatitis C: A Canadian Perspective. bioethics 2020;3:52-7. [DOI: 10.7202/1068763ar] [Reference Citation Analysis]
6 Pearce ME, Jongbloed K, Demerais L, MacDonald H, Christian WM, Sharma R, Pick N, Yoshida EM, Spittal PM, Klein MB. "Another thing to live for": Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. Int J Drug Policy 2019;74:52-61. [PMID: 31525640 DOI: 10.1016/j.drugpo.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
7 Jackson LA, Dechman M, Mathias H, Gahagan J, Morrison K. Safety and danger: Perceptions of the implementation of harm reduction programs in two communities in Nova Scotia, Canada. Health Soc Care Community 2021. [PMID: 34060676 DOI: 10.1111/hsc.13409] [Reference Citation Analysis]
8 O'Neil CR, Buss E, Plitt S, Osman M, Coffin CS, Charlton CL, Shafran S. Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada. Can J Public Health 2019;110:714-21. [PMID: 31222618 DOI: 10.17269/s41997-019-00234-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan SM. The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C. Can J Gastroenterol Hepatol 2016;2016:7603526. [PMID: 27843889 DOI: 10.1155/2016/7603526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]